Equities Analysts Offer Predictions for GLSI Q2 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Greenwich LifeSciences in a research note issued to investors on Tuesday, July 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.30) per share for the quarter, up from their prior estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $69.00 price target on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ FY2026 earnings at ($1.29) EPS and FY2027 earnings at ($1.17) EPS.

Several other brokerages also recently issued reports on GLSI. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen downgraded Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $57.00.

Greenwich LifeSciences Trading Down 1.6%

Shares of NASDAQ:GLSI opened at $12.98 on Thursday. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10. The company has a market capitalization of $190.55 million, a price-to-earnings ratio of -8.27 and a beta of 1.40. The firm’s 50-day moving average is $22.15 and its 200 day moving average is $24.37.

Institutional Investors Weigh In On Greenwich LifeSciences

Large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in shares of Greenwich LifeSciences during the fourth quarter valued at approximately $605,000. Geode Capital Management LLC increased its holdings in Greenwich LifeSciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after buying an additional 9,568 shares during the period. Vanguard Group Inc. increased its holdings in Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after buying an additional 13,179 shares during the period. State Street Corp raised its stake in Greenwich LifeSciences by 19.3% in the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after buying an additional 15,831 shares in the last quarter. Finally, Man Group plc bought a new position in Greenwich LifeSciences in the fourth quarter worth approximately $590,000. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.